A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: Challenges and therapeutic opportunities

Schizophrenia Research

Volumn 147, Issue 2-3, 2013, Pages 241-252

  Lindenmayer, Jean Pierre ^a   Nasrallah, Henry ^b   Pucci, Michael ^c   James, Steven ^d   Citrome, Leslie ^e,f  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c SCI Scientific Communications and Information   (United States)

^d SHIRE   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

^f NONE   (United States)

Author keywords

Amphetamine; Methylphenidate; Negative symptoms; Psychostimulants; Schizophrenia

Indexed keywords

AMPHETAMINE; ARMODAFINIL; CHLORPROMAZINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUPHENAZINE; HALOPERIDOL; IMIPRAMINE; ISOCARBOXAZID; LISDEXAMFETAMINE; METHYLPHENIDATE; MODAFINIL; NEUROLEPTIC AGENT; NORADRENALIN; OLANZAPINE; PALIPERIDONE; PLACEBO; PSYCHOSTIMULANT AGENT; RISPERIDONE; TRIFLUOPERAZINE;

ADD ON THERAPY; COGNITIVE DEFECT; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE CONTROL; DOPAMINE RELEASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG RESPONSE; FRONTAL CORTEX; HUMAN; INSOMNIA; LIMBIC SYSTEM; NEGATIVE SYNDROME; NEUROIMAGING; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SIDE EFFECT; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP; SYSTEMATIC REVIEW;

ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; DATABASES, BIBLIOGRAPHIC; DOPAMINE; HUMANS; SCHIZOPHRENIA;

EID: 84878967787     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.03.019     Document Type: Review

References (103)

1. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int. J. Neuropsychopharmacol. 2004, 7(Suppl. 1):S1-S5.
2. Abi-Dargham A., van de Giessen E., Slifstein M., Kegeles L.S., Laruelle M. Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. Biol. Psychiatry 2009, 65(12):1091-1093.
3. Aggarwal A., Garg A., Jiloha R.C. Psychotic relapse in a patient with schizophrenia associated with modafinil therapy. Prim. Psychiatr. 2009, 16(11):26-27.
4. Angrist B., Peselow E., Rubinstein M., Corwin J., Rotrosen J. Partial improvement in negative schizophrenic symptoms after amphetamine. Psychopharmacology (Berl) 1982, 78(2):128-130.
5. Angrist B., Peselow E., Rubinstein M., Wolkin A., Rotrosen J. Amphetamine response and relapse risk after depot neuroleptic discontinuation. Psychopharmacology (Berl) 1985, 85(3):277-283.
6. Arbabi M., Bagheri M., Rezaei F., Ahmadi-Abhari S.A., Tabrizi M., Khalighi-Sigaroudi F., Akhondzadeh S. A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia. Psychopharmacology (Berl) 2012, 220(3):591-598.
7. Barch D.M., Carter C.S. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr. Res. 2005, 77(1):43-58.
8. Beaulieu J.M., Gainetdinov R.R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 2011, 63(1):182-217.
9. Bertolino A., Breier A., Callicott J.H., Adler C., Mattay V.S., Shapiro M., Frank J.A., Pickar D., Weinberger D.R. The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia. Neuropsychopharmacology 2000, 22(2):125-132.
10. Bilder R.M., Lieberman J.A., Kim Y., Alvir J.M. Methylphenidate and neuroleptic effects on oral word production in schizophrenia. Neuropsychiatr. Neuropsychol. Behav. Neurol. 1992, 5(4):262-271.
11. Bobo W.V., Woodward N.D., Sim M.Y., Jayathilake K., Meltzer H.Y. The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: a randomized, double-blind, placebo-controlled trial. Schizophr. Res. 2012, 130(1-3):106-113.
12. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomais A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. U. S. A. 1997, 94(6):2569-2574.
13. Carnwath T., Garvey T., Holland M. The prescription of dexamphetamine to patients with schizophrenia and amphetamine dependence. J. Psychopharmacol. 2002, 16(4):373-377.
14. Carpenter M.D., Winsberg B.G., Camus L.A. Methylphenidate augmentation therapy in schizophrenia. J. Clin. Psychopharmacol. 1992, 12(4):273-275.
15. Casey J.F., Hollister L.E., Klett C.J., Lasky J.J., Caffey E.M. Combined drug therapy of chronic schizophrenics. Controlled evaluation of placebo, dextro-amphetamine, imipramine, isocarboxazid and trifluoperazine added to maintenance doses of chlorpromazine. Am. J. Psychiatry 1961, 117:997-1003.
16. Cesarec Z., Nyman A.K. Differential response to amphetamine in schizophrenia. Acta Psychiatr. Scand. 1985, 71(5):523-538.
17. Chertkow Y., Weinreb O., Youdim M.B., Silver H. Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia. J. Neural Transm. 2009, 116(11):1529-1541.
18. Chiarello R.J., Cole J.O. The use of psychostimulants in general psychiatry. A reconsideration. Arch. Gen. Psychiatry 1987, 44(3):286-295.
19. Curran C., Byrappa N., McBride A. Stimulant psychosis: systematic review. Br. J. Psychiatry 2004, 185:196-204.
20. Daniel D.G., Weinberger D.R., Jones D.W., Zigun J.R., Coppola R., Handel S., Bigelow L.B., Goldberg T.E., Berman K.F., Kleinman J.E. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J. Neurosci. 1991, 11(7):1907-1917.
21. Farrow T.F., Hunter M.D., Haque R., Spence S.A. Modafinil and unconstrained motor activity in schizophrenia: double-blind crossover placebo-controlled trial. Br. J. Psychiatry 2006, 189:461-462.
22. Featherstone R.E., Kapur S., Fletcher P.J. The amphetamine-induced sensitized state as a model of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31(8):1556-1571.
23. Findling R.L., Ginsberg L.D., Jain R., Gao J. Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study. J. Child Adolesc. Psychopharmacol. 2009, 19(6):649-662.
24. Foley K.F. Mechanism of action and therapeutic uses of psychostimulants. Clin. Lab. Sci. 2005, 18(2):107-113.
25. Fone K.C., Nutt D.J. Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Curr. Opin. Pharmacol. 2005, 5(1):87-93.
26. Foussias G., Remington G. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr. Bull. 2010, 36(2):359-369.
27. Freudenreich O., Henderson D.C., Macklin E.A., Evins A.E., Fan X., Cather C., Walsh J.P., Goff D.C. Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. J. Clin. Psychiatry 2009, 70(12):1674-1680.
28. Goff D.C. d-Cycloserine: an evolving role in learning and neuroplasticity in schizophrenia. Schizophr. Bull. 2012, 38(5):936-941.
29. Goff D.C., Hill M., Barch D. The treatment of cognitive impairment in schizophrenia. Pharmacol. Biochem. Behav. 2011, 99(2):245-253.
30. Goldberg T.E., Bigelow L.B., Weinberger D.R., Daniel D.G., Kleinman J.E. Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. Am. J. Psychiatry 1991, 148(1):78-84.
31. Goldman-Rakic P.S., Castner S.A., Svensson T.H., Siever L.J., Williams G.V. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) 2004, 174(1):3-16.
32. Goto Y., Grace A.A. The dopamine system and the pathophysiology of schizophrenia: a basic science perspective. Int. Rev. Neurobiol. 2007, 78:41-68.
33. Goto Y., Otani S., Grace A.A. The Yin and Yang of dopamine release: a new perspective. Neuropharmacology 2007, 53(5):583-587.
34. Gray J.A., Roth B.L. The pipeline and future of drug development in schizophrenia. Mol. Psychiatry 2007, 12(10):904-922.
35. Guillin O., Abi-Dargham A., Laruelle M. Neurobiology of dopamine in schizophrenia. Int. Rev. Neurobiol. 2007, 78:1-39.
36. Hanson E., Healey K., Wolf D., Kohler C. Assessment of pharmacotherapy for negative symptoms of schizophrenia. Curr. Psychiatry Rep. 2010, 12(6):563-571.
37. Heal D.J., Cheetham S.C., Smith S.L. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. Neuropharmacology 2009, 57(7-8):608-618.
38. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr. Bull. 2009, 35(3):549-562.
39. Hunter M.D., Ganesan V., Wilkinson I.D., Spence S.A. Impact of modafinil on prefrontal executive function in schizophrenia. Am. J. Psychiatry 2006, 163(12):2184-2186.
40. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148(10):1301-1308.
41. Jody D., Lieberman J.A., Geisler S., Szymanski S., Alvir J.M. Behavioral response to methylphenidate and treatment outcome in first episode schizophrenia. Psychopharmacol. Bull. 1990, 26(2):224-230.
42. Kane J.M., D'Souza D.C., Patkar A.A., Youakim J.M., Tiller J.M., Yang R., Keefe R.S. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. J. Clin. Psychiatry 2010, 71(11):1475-1481.
43. Kane J.M., Yang R., Youakim J.M. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study. Schizophr. Res. 2012, 135(1-3):116-122.
44. Kirkpatrick B., Fenton W.S., Carpenter W.T.J., Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 2006, 32(2):214-219.
45. Koreen A.R., Lieberman J.A., Alvir J., Chakos M. The behavioral effect of m-chlorophenylpiperazine (mCPP) and methylphenidate in first-episode schizophrenia and normal controls. Neuropsychopharmacology 1997, 16(1):61-68.
46. Krystal J.H., D'Souza D.C., Madonick S., Petrakis I.L. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophr. Res. 1999, 35(Suppl.):S35-S49.
47. Kumar R. Approved and investigational uses of modafinil: an evidence-based review. Drugs 2008, 68(13):1803-1839.
48. Laruelle M., Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J. Psychopharmacol. 1999, 13(4):358-371.
49. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. U. S. A. 1996, 93(17):9235-9240.
50. Laruelle M., Abi-Dargham A., Gil R., Kegeles L., Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol. Psychiatry 1999, 46(1):56-72.
51. Laruelle M., Abi-Dargham A., van D.C., Gil R., D'Souza D.C., Krystal J., Seibyl J., Baldwin R., Innis R. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. Biol. Psychiatry 2000, 47(5):371-379.
52. Laruelle M., Frankle W.G., Narendran R., Kegeles L.S., Abi-Dargham A. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. Clin. Ther. 2005, 27(Suppl. A):S16-S24.
53. Lasser R., Dirks B., Nasrallah H., Kirsch C., Gao J., Knesevich M., Lindenmayer J. Adjunctive lisdexamfetamine dimesylate treatment of predominant negative symptoms of schizophrenia in clinically stable adults maintained on atypical antipsychotic agents: a 14-week trial. Poster Presented at: 3rd Biennial Schizophrenia International Research Conference 2012, (14-18 April 2012; Florence, Italy).
54. Laughren T., Levin R. Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim. Schizophr. Bull. 2006, 32(2):220-222.
55. Laughren T., Levin R. Food and Drug Administration commentary on methodological issues in negative symptom trials. Schizophr. Bull. 2011, 37(2):255-256.
56. LeDuc P.A., Mittleman G. Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence. Psychopharmacology (Berl) 1995, 121(4):407-427.
57. Levy D.L., Smith M., Robinson D., Jody D., Lerner G., Alvir J., Geisler S.H., Szymanski S.R., Gonzalez A., Mayerhoff D.I. Methylphenidate increases thought disorder in recent onset schizophrenics, but not in normal controls. Biol. Psychiatry 1993, 34(8):507-514.
58. Lieberman J.A., Kane J.M., Gadaleta D., Brenner R., Lesser M.S., Kinon B. Methylphenidate challenge as a predictor of relapse in schizophrenia. Am. J. Psychiatry 1984, 141(5):633-638.
59. Lieberman J.A., Kane J.M., Sarantakos S., Gadaletta D., Woerner M., Alvir J., Ramos-Lorenzi J. Prediction of relapse in schizophrenia. Psychopharmacol. Bull. 1986, 22(3):845-853.
60. Lieberman J.A., Kane J.M., Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 1987, 91(4):415-433.
61. Lieberman J.A., Kane J.M., Sarantakos S., Gadaleta D., Woerner M., Alvir J., Ramos-Lorenzi J. Prediction of relapse in schizophrenia. Arch. Gen. Psychiatry 1987, 44(7):597-603.
62. Lieberman J., Jody D., Geisler S., Alvir J., Loebel A., Szymanski S., Woerner M., Borenstein M. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch. Gen. Psychiatry 1993, 50(5):369-376.
63. Lieberman J.A., Alvir J., Geisler S., Ramos-Lorenzi J., Woerner M., Novacenko H., Cooper T., Kane J.M. Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia. Neuropsychopharmacology 1994, 11(2):107-118.
64. Little K.Y., Gay T.L., Vore M. Predictors of response to high dose antipsychotics in chronic schizophrenics. Psychiatry Res. 1989, 30(1):1-9.
65. Mathew R.J., Wilson W.H. Changes in cerebral blood flow and mental state after amphetamine challenge in schizophrenic patients. Neuropsychobiology 1989, 21(3):117-123.
66. Milev P., Ho B.C., Arndt S., Andreasen N.C. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am. J. Psychiatry 2005, 162(3):495-506.
67. Moncrieff J. A critique of the dopamine hypothesis of schizophrenia and psychosis. Harv. Rev. Psychiatry 2009, 17(3):214-225.
68. Mu Q., Johnson K., Morgan P.S., Grenesko E.L., Molnar C.E., Anderson B., Nahas Z., Kozel F.A., Kose S., Knable M., Fernandes P., Nichols D.E., Mailman R.B., George M.S. A single 20mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophr. Res. 2007, 94(1-3):332-341.
69. Nyman A.K. Nonregressive schizophrenia-a long-term comparative follow-up investigation. Acta Psychiatr. Scand. 1989, 79(1):59-73.
70. Nyman G.E., Nyman A.K., Nylander B.I. Non-regressive schizophrenia. I. A comparative study of clinical picture, social prognosis, and heredity. Acta Psychiatr. Scand. 1978, 57(2):165-192.
71. Pandurangi A.K., Goldberg S.C., Brink D.D., Hill M.H., Gulati A.N., Hamer R.M. Amphetamine challenge test, response to treatment, and lateral ventricle size in schizophrenia. Biol. Psychiatry 1989, 25(2):207-214.
72. Pierre J.M., Peloian J.H., Wirshing D.A., Wirshing W.C., Marder S.R. A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. J. Clin. Psychiatry 2007, 68(5):705-710.
73. Pietrzak R.H., Snyder P.J., Maruff P. Amphetamine-related improvement in executive function in patients with chronic schizophrenia is modulated by practice effects. Schizophr. Res. 2010, 124(1-3):176-182.
74. Pietrzak R.H., Snyder P.J., Maruff P. Use of an acute challenge with d-amphetamine to model cognitive improvement in chronic schizophrenia. Hum. Psychopharmacol. 2010, 25(4):353-358.
75. Rector N.A., Beck A.T., Stolar N. The negative symptoms of schizophrenia: a cognitive perspective. Can. J. Psychiatry 2005, 50(5):247-257.
76. Robinson D., Mayerhoff D., Alvir J., Cooper T., Lieberman J. Mood responses of remitted schizophrenics to methylphenidate infusion. Psychopharmacology (Berl) 1991, 105(2):247-252.
77. Robinson D., Woerner M.G., Alvir J.M., Bilder R., Goldman R., Geisler S., Koreen A., Sheitman B., Chakos M., Mayerhoff D., Lieberman J.A. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry 1999, 56(3):241-247.
78. Robinson D.G., Woerner M.G., Alvir J.M., Geisler S., Koreen A., Sheitman B., Chakos M., Mayerhoff D., Bilder R., Goldman R., Lieberman J.A. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry 1999, 156(4):544-549.
79. Rosenthal M.H., Bryant S.L. Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia. Clin. Neuropharmacol. 2004, 27(1):38-43.
80. Rummel C., Kissling W., Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst. Rev. 2006, 3:CD005581.
81. Sanfilipo M., Wolkin A., Angrist B., van Kammen D.P., Duncan E., Wieland S., Cooper T.B., Peselow E.D., Rotrosen J. Amphetamine and negative symptoms of schizophrenia. Psychopharmacology (Berl) 1996, 123(2):211-214.
82. Schmitz Y., Benoit-Marand M., Gonon F., Sulzer D. Presynaptic regulation of dopaminergic neurotransmission. J. Neurochem. 2003, 87(2):273-289.
83. Scoriels L., Barnett J.H., Murray G.K., Cherukuru S., Fielding M., Cheng F., Lennox B.R., Sahakian B.J., Jones P.B. Effects of modafinil on emotional processing in first episode psychosis. Biol. Psychiatry 2011, 69(5):457-464.
84. Serper M.R., Alpert M., Richardson N.A., Dickson S., Allen M.H., Werner A. Clinical effects of recent cocaine use on patients with acute schizophrenia. Am. J. Psychiatry 1995, 152(10):1464-1469.
85. Sevy S., Rosenthal M.H., Alvir J., Meyer S., Visweswaraiah H., Gunduz-Bruce H., Schooler N.R. Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. J. Clin. Psychiatry 2005, 66(7):839-843.
86. Sharma R.P., Javaid J.I., Pandey G.N., Janicak P.G., Davis J.M. Behavioral and biochemical effects of methylphenidate in schizophrenic and nonschizophrenic patients. Biol. Psychiatry 1991, 30(5):459-466.
87. Singh S.P., Singh V., Kar N., Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br. J. Psychiatry 2010, 197(3):174-179.
88. Spence S.A., Green R.D., Wilkinson I.D., Hunter M.D. Modafinil modulates anterior cingulate function in chronic schizophrenia. Br. J. Psychiatry 2005, 187:55-61.
89. Srisurapanont M., Ali R., Marsden J., Sunga A., Wada K., Monteiro M. Psychotic symptoms in methamphetamine psychotic in-patients. Int. J. Neuropsychopharmacol. 2003, 6(4):347-352.
90. Stahl S.M. Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophrenia. CNS. Spectr. 2007, 12(4):265-268.
91. Stahl S.M., Buckley P.F. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr. Scand. 2007, 115(1):4-11.
92. Strakowski S.M., Sax K.W., Setters M.J., Stanton S.P., Keck P.E. Lack of enhanced response to repeated d-amphetamine challenge in first-episode psychosis: implications for a sensitization model of psychosis in humans. Biol. Psychiatry 1997, 42(9):749-755.
93. Szeszko P.R., Bilder R.M., Dunlop J.A., Walder D.J., Lieberman J.A. Longitudinal assessment of methylphenidate effects on oral word production and symptoms in first-episode schizophrenia at acute and stabilized phases. Biol. Psychiatry 1999, 45(6):680-686.
94. Tamminga C.A. The neurobiology of cognition in schizophrenia. J. Clin. Psychiatry 2006, 67(Suppl. 9):9-13.
95. Thompson J.L., Urban N., Abi-Dargham A. How have developments in molecular imaging techniques furthered schizophrenia research?. Imaging Med. 2009, 1(2):135-153.
96. Toda M., Abi-Dargham A. Dopamine hypothesis of schizophrenia: making sense of it all. Curr. Psychiatry Rep. 2007, 9(4):329-336.
97. Turner D.C., Clark L., Pomarol-Clotet E., McKenna P., Robbins T.W., Sahakian B.J. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 2004, 29(7):1363-1373.
98. US Department of Health and Human Services Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings 2011, The National Institute on Drug Abuse (NIDA), (http://www.samhsa.gov/data/nsduh/2k10nsduh/2k10results.htm. Accessed January 3, 2013).
99. van Kammen D.P., Boronow J.J. Dextro-amphetamine diminishes negative symptoms in schizophrenia. Int. Clin. Psychopharmacol. 1988, 3(2):111-121.
100. Volkow N.D., Fowler J.S., Logan J., Alexoff D., Zhu W., Telang F., Wang G.J., Jayne M., Hooker J.M., Wong C., Hubbard B., Carter P., Warner D., King P., Shea C., Xu Y., Muench L., Apelskog-Torres K. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 2009, 301(11):1148-1154.
101. Wittkampf L.C., Arends J., Timmerman L., Lancel M. A review of modafinil and armodafinil as add-on therapy in antipsychotic treated patients with schizophrenia. Ther. Adv. Psychopharmacol. 2012, 2(4):115-125.
102. Wolkin A., Sanfilipo M., Angrist B., Duncan E., Wieland S., Wolf A.P., Brodie J.D., Cooper T.B., Laska E., Rotrosen J.P. Acute d-amphetamine challenge in schizophrenia: effects on cerebral glucose utilization and clinical symptomatology. Biol. Psychiatry 1994, 36(5):317-325.
103. Yamamoto K., Hornykiewicz O. Proposal for a noradrenaline hypothesis of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28(5):913-922.